Geode Capital Management LLC Purchases 67,813 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN)

Geode Capital Management LLC increased its stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 9.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 750,208 shares of the company's stock after purchasing an additional 67,813 shares during the period. Geode Capital Management LLC owned 1.59% of Enliven Therapeutics worth $19,164,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in ELVN. FMR LLC lifted its stake in Enliven Therapeutics by 10.6% in the third quarter. FMR LLC now owns 6,296,179 shares of the company's stock valued at $160,804,000 after buying an additional 601,611 shares during the last quarter. First Turn Management LLC bought a new position in shares of Enliven Therapeutics during the second quarter worth about $9,657,000. Janus Henderson Group PLC increased its holdings in shares of Enliven Therapeutics by 43.0% in the 3rd quarter. Janus Henderson Group PLC now owns 1,041,724 shares of the company's stock worth $26,611,000 after acquiring an additional 313,019 shares during the period. Ally Bridge Group NY LLC bought a new stake in Enliven Therapeutics in the 3rd quarter valued at about $5,998,000. Finally, Marshall Wace LLP acquired a new position in Enliven Therapeutics during the 2nd quarter valued at about $4,489,000. Institutional investors and hedge funds own 95.08% of the company's stock.

Enliven Therapeutics Trading Down 1.5 %

NASDAQ ELVN traded down $0.34 during trading on Friday, reaching $22.37. The company's stock had a trading volume of 255,845 shares, compared to its average volume of 170,189. The business has a 50-day moving average price of $25.58 and a 200-day moving average price of $24.28. Enliven Therapeutics, Inc. has a 1-year low of $10.90 and a 1-year high of $30.03. The stock has a market capitalization of $1.09 billion, a PE ratio of -11.77 and a beta of 1.02.

Insider Activity

In other Enliven Therapeutics news, insider Joseph P. Lyssikatos sold 37,878 shares of the company's stock in a transaction that occurred on Wednesday, October 9th. The stock was sold at an average price of $28.16, for a total transaction of $1,066,644.48. Following the completion of the sale, the insider now owns 1,016,035 shares of the company's stock, valued at $28,611,545.60. This represents a 3.59 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Benjamin Hohl sold 5,250 shares of the stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $24.89, for a total value of $130,672.50. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 124,945 shares of company stock worth $3,478,624. 29.20% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several brokerages have commented on ELVN. HC Wainwright restated a "buy" rating and issued a $37.00 price target on shares of Enliven Therapeutics in a research note on Tuesday, October 1st. Robert W. Baird raised their target price on Enliven Therapeutics from $32.00 to $40.00 and gave the company an "outperform" rating in a research report on Friday, November 15th. Finally, BTIG Research started coverage on shares of Enliven Therapeutics in a research report on Friday, December 13th. They issued a "buy" rating and a $42.00 price target for the company. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Buy" and an average price target of $38.25.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.